Sumitomo Chemical India share price today

Sumitomo Chemical India Ltd's share price was ₹328.10 at the close on 4 November 2026. It has been falling for 2 weeks. That is 29.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹315 and ₹565, and at that close it sat 5% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sumitomo Chemical India Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running.

Over the last 6.8 years the share price moved +42% while the NIFTY 500 moved +120%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, profit fell in the September 2026 quarter and operating margin down 3 points on a year earlier.

1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row

   From 7% to 9.7% of the company by the September 2026 quarter.

2. Profit fell in the September 2026 quarter

   Profit was ₹157 crore, -11.8% on a year earlier (₹178 crore), after 2 quarters of growth.

   Next results: check that stock levels fall as the company's fixes take hold.

   From the earnings call on 27 Oct 2026.

3. Operating margin down 3 points on a year earlier

   20% in the September 2026 quarter, from 23%.

   Next results: check whether margins return to the normal historical range.

   From the earnings call on 27 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Sumitomo Chemical India reported revenue of ₹907 crore, down 2.5% from ₹930 crore a year earlier, and a profit of ₹157 crore, down 11.8% from ₹178 crore.

Sumitomo Chemical India results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Sumitomo Chemical India's management discussed these results on a call held on 27 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sumitomo Chemical India closed at ₹328.10 on 4 November 2026, down 30.9% from ₹475.15 a year earlier (7 November 2025) and down 15.8% over five years. Its highest weekly close since February 2020 was ₹630.65 on 1 August 2025.

Sumitomo Chemical India share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

357 weekly closes from 1 February 2020 to 4 November 2026.

4 Nov 2026: Sumitomo Chemical India closed at ₹328.10, up 4.1% on the week and down 21.4% on the month. 27 Oct 2026: Sumitomo Chemical India held its results call for July to September 2026. Management guided: H2 sales planned above last year where markets allow, while parent-company exports remain soft; broader normalization expected next year.

Earlier

• Results for July to September 2026: Revenue down 2.5% and profit down 11.8% on a year earlier.
• Our read, 22 Aug 2026: The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger.,New products, herbicides and price actions are the named demand and margin levers.,The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season.
• 17 Jul 2026: ex-date for a dividend of ₹1.30 a share.

Our read of the business

The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger.,New products, herbicides and price actions are the named demand and margin levers.,The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season.

April to June 2026: Revenue and reported profit improved against the comparable quarter, with operating margin higher.

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Sumitomo Chemical India paid ₹1.30 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.40% at the ₹328.10 close on 4 November 2026. The last was a dividend of ₹1.30 a share, ex-date 17 July 2026.

Sumitomo Chemical India dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Sumitomo Chemical India Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 8 of its last 9 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 27 October 2026, Sumitomo Chemical India's management guided: H2 sales planned above last year where markets allow, while parent-company exports remain soft; broader normalization expected next year.

“Our goal for H2 is to grow over last year's sales where the market allows, while protecting profitability.”Dr. Suresh Ramachandran, on the call for July to September 2026

What management guided

• H2 margins expected in the normal historical range, inventory expected to normalize, and sales returns not expected to affect H2.
• Dahej ₹150 crore herbicide-intermediate project: commercial production July to September 2028 (July-October 2028), payback under 5 years and company-level margins.
• Tarapur additions: ₹10 crore each across two projects, adding 3-4 products; first part within FY27, second by FY28-end.
• Top Grain full-country rollout planned next season, including wheat in February-March; 1-2 specialty molecules tested annually, with commercialization after 4-5 years; innovation index goal 9-10%.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 27 October 2026.

What is changing at Sumitomo Chemical India, from the latest results and calls: specialty and herbicide mix, calibrated price pass-through and innovation access from parent.

• Specialty and herbicide mix. Specialty products and herbicides are the principal revenue-mix levers. ✓ fact
• Calibrated price pass-through. Successive product-specific price actions are intended to protect margins from input and freight inflation. ✓ fact
• Innovation access from parent. India's higher testing role can shorten the path from parent technology to local launches. ✓ fact
• Self-funded backward integration. Cash generation can fund Dahej and Tarapur projects without a financing dependency. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.

Each change stops working if

• Specialty and herbicide mix: Specialty launches do not gain repeat demand or channel returns rise.
• Calibrated price pass-through: Farmer demand weakens after price increases or competitors discount aggressively.
• Innovation access from parent: Testing does not convert into registrations and commercial launches.
• Self-funded backward integration: Projects are deferred again or capital spending does not create a cost or supply advantage.

The main risks

• Monsoon and farm-demand volatility: Kharif demand depends on rainfall timing and distribution. ⚠ estimate
• Input-cost and competitive pass-through: Raw material, packaging, solvent and freight inflation can pressure margin if price actions fail. ⚠ estimate
• Capital spending execution and timeline slippage: Dahej and Tarapur economics arrive later if approvals or construction move again. ⚠ estimate
• Export and logistics disruption: Shipment delays and container constraints can interrupt export conversion. ⚠ estimate

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Sumitomo Chemical India reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Parent-company export shipments should show destocking unwind; compare Japanese flows with third-party demand.

Sumitomo Chemical India is on 2 of our India lists: 52 week high & low and Small & mid cap stocks.

Sumitomo Chemical India Ltd earned ₹157 Cr of net profit in the Sep 2026 quarter, −11.8% on the same quarter a year earlier. Full-year FY26 profit was ₹543 Cr. Over 8 years profit has grown 17.9% a year on average. That is 17.3% of the quarter's revenue. The same quarter a year earlier earned ₹178 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹543 Cr (+7.3% on the year before).

Why profit moved: revenue changed −2.5% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +1.9% and revenue −3.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Sumitomo Chemical India Ltd reported ₹907 Cr of revenue in the Sep 2026 quarter, −2.5% on the same quarter a year earlier. Over 8 years it has grown 6.8% a year on average. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,222 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Management links margin expansion to specialty mix, with recently launched products becoming a larger part of domestic revenue. Herbicide growth and branded formulations provide evidence that this is a product-mix story rather than only broad pricing.

FY26 revenue was ₹3,238 Cr, +2.8% on the year before.

Recent pace: the last four quarters grew −3.2% on average, against 6.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −2.6%, against +2.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +2.9%, against +7.4% a year (rolling over).

Sumitomo Chemical India Ltd's operating margin was 20.0% in the Sep 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 9 years it has been between 11.0% and 21.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −2.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 117% of Sumitomo Chemical India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹446 Cr of operating cash against ₹543 Cr of profit. After ₹79.0 Cr of spending on assets, ₹367 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. The cash record shows free cash generation over the multi-year window and management describes internal cash and retained earnings as the capex funding source. The Capex Inflection Point model applies only after project commissioning and revenue conversion.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 117% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Sumitomo Chemical India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 163 days in FY26, up from 157 days in FY21. It spent ₹290 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 166 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,238 Cr, each day of that cycle ties up about ₹8.9 Cr, so roughly ₹1,446 Cr is tied up in the business at any time.

FY26: customers took 83 days to pay and stock sat for 166 days, about 5.5 months of sales sitting as stock, for a full cycle of 163 days, longer than FY21's 157.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 166 days. Customers pay about 83 days after that. Suppliers are paid at 86 days. Together that makes the 163-day cycle.

Spending on assets: ₹290 Cr over the last 3 years, against ₹194 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Sumitomo Chemical India Ltd's P/E is 29.8×, about the lowest it has ever been. Its usual P/E (the middle reading) is 51.7×, over 6.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹11.20.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved +7.4% while the price moved −30.9%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved −3.4% a year; about +8.3% a year came from earnings growth and about −11.7 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Sumitomo Chemical India Ltd's business is growing steadily. Profit and EPS growth have stayed positive throughout, and ROCE is steady at 21.3%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sumitomo Chemical India Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: EARLY EXPANSION. Still open: A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.

NOT YET CHECKED

From the numbers. The operating and price curves indicate early expansion with price below its prior peak.

From the price. Price stage 4, week 2, below its 200-day line, relative strength falling.

Where they disagree. The operating and price curves indicate early expansion with price below its prior peak.

What is not proven yet. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.

What would change our mind. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.

The test written in advance. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. Measured by: the thesis as written as stated by the next result.

The test written in advance. Monsoon and farm-demand volatility. Measured by: Monsoon and farm-demand volatility Domestic revenue declines year on year during the Kharif quarter. by the next result.

What the company does. The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger. New products, herbicides and price actions are the named demand and margin levers. The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

What the surface reading misses. The surface reading is: Cash generation broadly tracks reported earnings. The research reads it further: The multi-year result is supported by free cash generation, although latest-year conversion is lower because working capital absorbed cash.

• 1 · Operating leveragequiet
• 2 · Value-added mixbuilding
• 3 · Management changequiet
• 4 · Paying down debtquiet
• 5 · Regulatory approvalquiet
• 6 · Order-book winsquiet
• 7 · Consolidationquiet
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesquiet
• 11 · More business from existing customersquiet
• 12 · New product launchquiet
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 2 · Value-added mix: building. Specialty products and herbicides are the principal revenue-mix levers. What proves it keeps working: Specialty and herbicide mix. It stops working if Specialty launches do not gain repeat demand or channel returns rise.

Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

What Sumitomo Chemical India Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Semiconductor Role Has Become Uncertain · 27 October 2026. In Oct 2025 and May 2026, management described SCIL as actively involved in the semiconductor discussions and planned bringing the business into the listed entity. In Oct 2026, management said that no concrete structure or specific role had been defined, materially reducing the certainty around a previously presented strategic growth opportunity without explaining the change.

Capital Deployment Commitment Softened · 27 October 2026. The Oct 2025 and May 2026 calls framed Dahej and other capex as the intended destination for a large share of accumulated cash. In Oct 2026, management said cash deployment was a smaller part of the agenda and offered no definitive timeline. Although the announced projects remain on track and management did not state that cash would be returned, the scale and urgency of deployment have materially changed without explanation.

Dahej Timeline Is Internally Conflicted · 27 October 2026. The Oct 2025 call pointed to revenue generation sometime in calendar year 2028 after an implementation period of 18 months to 2 years.

Dahej Project Timeline Slippage · 28 October 2025. The timeline for the strategic Dahej greenfield project has been pushed back without explanation. In the May 2025 call, management stated initial manufacturing would deliver products starting in 2027. However, in the October 2025 call, the first revenue from the project is now expected in 2028, representing a delay of at least one year for this key growth initiative. Earlier call (May 2025): “we want to start manufacturing certain products to deliver between”. Later call (Oct 2025): “we expect that during this current financial year some of these project should go and get approved. with implementation timelines of 18 months to two years. So maybe sometime in calendar year 2028 we see that that some of these projects should start generating revenues.”

Every quote above is taken word for word from the company’s own earnings calls.

Sumitomo Chemical India Ltd earned a ROCE of 22% in FY26. That is up from a low of 20% in FY24. Its return on capital used (ROIC) is 5.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.8% net margin and 0.72× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 16.8% net margin × 0.72× asset turnover × 1.32× leverage (assets divided by equity) ≈ 16.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 17.5% − 12.0% = +5.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 17.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 23.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Sumitomo Chemical India Ltd has total debt of ₹56.0 Cr against shareholder equity of ₹3,701 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Sumitomo Chemical India Ltd by 2.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.7% of the company. Foreign institutions moved −0.6 points over the same period, to 2.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +2.7 points over 8 quarters, to 9.7%; Foreign institutions: −0.6 points over 8 quarters, to 2.9%; Promoters: +0.0 points over 8 quarters, to 75.0%.

Why the owners changed: domestic institutions drove it (+2.7 points), with the other side taken by foreign institutions (−0.6 points). They raised their stake step by step.